NASH - Nonalcoholic Steatohepatitis
Conditions
Brief summary
This is a companion study assessing the ¹³C-Methacetin Breath Test (MBT) in subjects participating in the Bristol Myers-Squibb (BMS) NCT03486899 and NCT03486912 referenced studies using study drug BMS-986036.
Detailed description
Subjects that are enrolled into either of two separate BMS sponsored IND (Investigational New Drug) studies (referenced by NCT03486899 and NCT03486912) at selected study sites will be offered the opportunity to perform the MBT. These will be considered as two separate study cohorts (cohort 1 and 2 respectively) within this companion protocol. There are four (4) treatment arms (BMS-986036 Dose Level 1, Dose Level 2, Dose Level 3 or matching placebo), as defined in the respective BMS sponsored protocols. Cohort 1 consists of Subjects with NASH and stage 3 fibrosis, as assessed by a central laboratory reader of the liver biopsies (up to 160), and who meet all the NCT03486899 referenced study criteria. Cohort 2 consists of Subjects with NASH and compensated liver cirrhosis, as assessed by a central laboratory reader of the liver biopsies (up to100), and who meet all the NCT03486912 referenced study criteria. Approximately 75 sites will be included in the BMS studies, but not all participating sites will elect to perform the MBT. Each subject will perform up to 3 MBTs over 1 year; approximately one every 24 weeks. The MBT in this study will only be conducted in the USA. The primary purpose of the BMS study is to assess an experimental treatment for the following conditions: Hepatic cirrhosis, liver fibrosis, Nonalcoholic Fatty Liver Disease (NAFLD) and NASH (Nonalcoholic Steatohepatitis).
Interventions
COMBINATION_PRODUCT¹³C-Methacetin Breath Test
A breath analyzer will be used to measure changes in 12C (carbon 12) to 13C (carbon 13) ratio as a result of metabolism of the Methacetin substrate before and after treatment.
DRUGBMS-986036
Investigational drug for NASH treatment in Main BMS protocol
DEVICEBreathID MCS device
The BreathID MCS device is a breath analyzer specifically used for measuring changes in the ratio of 13CO2 and 12CO2 isotopes of carbon dioxide. The device is connected to the subject via a nasal cannula and breath is passively collected before and after ingestion of labelled 13C- Methacetin substrate.
Sponsors
Bristol-Myers Squibb
Meridian Bioscience, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
The collaborator is responsible for the masking process.
Intervention model description
Subjects will be enrolled and randomized via interactive response technology (IRT) to receive BMS-9860936 Dose Level 1 , BMS-986036 Dose Level 2, BMS-9860936 Dose Level 3 or matching placebo in a 1:1:1:1 ratio. in both Stage 3 liver fibrosis and cirrhosis cohorts.
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Liver biopsy performed within 6 months prior to the Screening Visit; if not performed within 6 months prior to the Screening Visit, a liver biopsy will be performed during the Screening Period and at least 4 weeks prior to randomization (Biopsy must be consistent with NASH, with: a) A score of at least 1 for each NAS component (steatosis, lobular inflammation, and ballooning), as assessed by the central reader AND b) Stage 3/Stage 4 (Cirrhosis) liver fibrosis (cohort 1 and cohort 2 respectively) according to the NASH CRN (Clinical Research Network) classification, as assessed by the central reader 2. Participants taking anti-diabetic, anti-obesity, or anti-dyslipidemic medications must have been on stable dosing regimens for at least 3 months prior to the Screening Visit 3. Participants taking vitamin E at doses ≥800 IU/day must have been on stable doses for at least 6 months prior to the Screening Visit (Vitamin E treatment must not have been initiated after the liver biopsy was performed)-
Exclusion criteria
1. Other causes of liver disease (e.g., alcoholic liver disease, hepatitis B virus infection, chronic hepatitis C virus infection, autoimmune hepatitis, drug-induced hepatotoxicity, Wilson disease, alpha-1-antitrypsin deficiency, iron overload, and hemochromatosis) 2. Current or past history of hepatocellular carcinoma (HCC) 3. Past or current evidence of hepatic decompensation (e.g., ascites, variceal bleeding, hepatic encephalopathy and/or spontaneous bacterial peritonitis) or liver transplantation Other protocol defined inclusion/
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percent Change in MBT From Day 1 to Week 48 | 48 weeks | Identification of subjects that experience a change in metabolic capacity in each of the treatment arms versus placebo arm after 48 weeks compared to baseline as determined independently by the Methacetin Breath Test (MBT) PDR peak output parameter under a responder analysis. No actual cut-off values or specific values of percent change criteria were pre-specified since this study was solely exploratory by nature as described in the protocol. The MBT PDR peak parameter was collected and analyzed for all those that performed the MBT based on the initial eligibility criteria of the study protocol and obtained a valid device printout with a PDR peak result, with no other methods or criteria used to exclude subjects. The outcome measure PDR peak is automatically calculated and generated in the printout when the device completes its measuring. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Subjects That Experience Deterioration Events | 48 weeks | Binary diagnosis of subjects that experience deterioration event as determined by the MBT compared to the placebo treatment arm |
| Correlation | 48 weeks | Correlation of MBT PDR Peak to biopsy proven changes in fibrosis and/or NAS (NAFLD Activity Score) from Day 1 to Week 48. Total NAS score represents the sum of scores for steatosis (0-3), lobular inflammation (0-3), and ballooning (0-2), and ranges from 0-8; where 8 is the most severe. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| BMS-986036 Dose Level 1 10 mg Administered by subcutaneous injection
¹³C-Methacetin Breath Test: A breath analyzer will be used to measure changes in 12C (carbon 12) to 13C (carbon 13) ratio as a result of metabolism of the Methacetin substrate before and after treatment.
BMS-986036: Investigational drug for NASH treatment in Main BMS protocol
BreathID MCS device: The BreathID MCS device is a breath analyzer specifically used for measuring changes in the ratio of 13CO2 and 12CO2 isotopes of carbon dioxide. The device is connected to the subject via a nasal cannula and breath is passively collected before and after ingestion of labelled 13C- Methacetin substrate. | 32 |
| BMS-986036 Dose Level 2 20 mg Administered by subcutaneous injection
¹³C-Methacetin Breath Test: A breath analyzer will be used to measure changes in 12C (carbon 12) to 13C (carbon 13) ratio as a result of metabolism of the Methacetin substrate before and after treatment.
BMS-986036: Investigational drug for NASH treatment in Main BMS protocol
BreathID MCS device: The BreathID MCS device is a breath analyzer specifically used for measuring changes in the ratio of 13CO2 and 12CO2 isotopes of carbon dioxide. The device is connected to the subject via a nasal cannula and breath is passively collected before and after ingestion of labelled 13C- Methacetin substrate. | 32 |
| BMS-986036 Dose Level 3 40 mg Administered by subcutaneous injection
¹³C-Methacetin Breath Test: A breath analyzer will be used to measure changes in 12C (carbon 12) to 13C (carbon 13) ratio as a result of metabolism of the Methacetin substrate before and after treatment.
BMS-986036: Investigational drug for NASH treatment in Main BMS protocol
BreathID MCS device: The BreathID MCS device is a breath analyzer specifically used for measuring changes in the ratio of 13CO2 and 12CO2 isotopes of carbon dioxide. The device is connected to the subject via a nasal cannula and breath is passively collected before and after ingestion of labelled 13C- Methacetin substrate. | 30 |
| Placebo Administered by subcutaneous injection
¹³C-Methacetin Breath Test: A breath analyzer will be used to measure changes in 12C (carbon 12) to 13C (carbon 13) ratio as a result of metabolism of the Methacetin substrate before and after treatment.
BMS-986036: Investigational drug for NASH treatment in Main BMS protocol
BreathID MCS device: The BreathID MCS device is a breath analyzer specifically used for measuring changes in the ratio of 13CO2 and 12CO2 isotopes of carbon dioxide. The device is connected to the subject via a nasal cannula and breath is passively collected before and after ingestion of labelled 13C- Methacetin substrate. | 30 |
| Total | 124 |
Baseline characteristics
| Characteristic | BMS-986036 Dose Level 1 10 mg | Total | Placebo | BMS-986036 Dose Level 3 40 mg | BMS-986036 Dose Level 2 20 mg |
|---|---|---|---|---|---|
| Age, Continuous | 58.906 years STANDARD_DEVIATION 6.981 | 59.2 years STANDARD_DEVIATION 8.39 | 60.433 years STANDARD_DEVIATION 7.338 | 59.2 years STANDARD_DEVIATION 9.034 | 58.438 years STANDARD_DEVIATION 10.096 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 3 Participants | 0 Participants | 0 Participants | 3 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 4 Participants | 8 Participants | 3 Participants | 1 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 28 Participants | 113 Participants | 27 Participants | 29 Participants | 29 Participants |
| Region of Enrollment United States | 32 participants | 124 participants | 30 participants | 30 participants | 32 participants |
| Sex: Female, Male Female | 24 Participants | 78 Participants | 17 Participants | 17 Participants | 20 Participants |
| Sex: Female, Male Male | 8 Participants | 46 Participants | 13 Participants | 13 Participants | 12 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 32 | 0 / 32 | 0 / 30 | 0 / 30 |
| other Total, other adverse events | 0 / 32 | 0 / 32 | 0 / 30 | 0 / 30 |
| serious Total, serious adverse events | 0 / 32 | 0 / 32 | 0 / 30 | 0 / 30 |
Outcome results
Primary
Percent Change in MBT From Day 1 to Week 48
Identification of subjects that experience a change in metabolic capacity in each of the treatment arms versus placebo arm after 48 weeks compared to baseline as determined independently by the Methacetin Breath Test (MBT) PDR peak output parameter under a responder analysis. No actual cut-off values or specific values of percent change criteria were pre-specified since this study was solely exploratory by nature as described in the protocol. The MBT PDR peak parameter was collected and analyzed for all those that performed the MBT based on the initial eligibility criteria of the study protocol and obtained a valid device printout with a PDR peak result, with no other methods or criteria used to exclude subjects. The outcome measure PDR peak is automatically calculated and generated in the printout when the device completes its measuring.
Time frame: 48 weeks
Population: Percent Change in PDR peak (MBT parameter) from Day 1 to Week 48 in the Safety Analysis Set (Intended to be treated). Due to COVID-19, a follow up MBT at Week 48 was partial and did not include all those that performed the initial MBT on Day 1..
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| BMS-986036 Dose Level 1 10 mg | Percent Change in MBT From Day 1 to Week 48 | 8.8 percentage of change in MBT | Standard Deviation 32.51 |
| BMS-986036 Dose Level 2 20 mg | Percent Change in MBT From Day 1 to Week 48 | 12.3 percentage of change in MBT | Standard Deviation 33.36 |
| BMS-986036 Dose Level 3 40 mg | Percent Change in MBT From Day 1 to Week 48 | -4.7 percentage of change in MBT | Standard Deviation 27.64 |
| Placebo | Percent Change in MBT From Day 1 to Week 48 | 15.3 percentage of change in MBT | Standard Deviation 31.58 |
Secondary
Correlation
Correlation of MBT PDR Peak to biopsy proven changes in fibrosis and/or NAS (NAFLD Activity Score) from Day 1 to Week 48. Total NAS score represents the sum of scores for steatosis (0-3), lobular inflammation (0-3), and ballooning (0-2), and ranges from 0-8; where 8 is the most severe.
Time frame: 48 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| BMS-986036 Dose Level 1 10 mg | Correlation | -0.324 r-correlation |
| BMS-986036 Dose Level 2 20 mg | Correlation | -0.501 r-correlation |
| BMS-986036 Dose Level 3 40 mg | Correlation | 0.275 r-correlation |
| Placebo | Correlation | -0.313 r-correlation |
Secondary
Correlation
Correlation of MBT changes to changes in liver stiffness as measured by Magnetic Resonance Elastography (MRE) from Day 1 to Week 48
Time frame: 48 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| BMS-986036 Dose Level 1 10 mg | Correlation | 0.279 r-correlation |
| BMS-986036 Dose Level 2 20 mg | Correlation | -0.115 r-correlation |
| BMS-986036 Dose Level 3 40 mg | Correlation | -0.428 r-correlation |
| Placebo | Correlation | 0.242 r-correlation |
Secondary
Correlation
Correlation of MBT changes to changes in Proton Density Fat Fraction (PDFF) as measured by Magnetic Resonance Imaging(MRI) from Day 1 to Week 48
Time frame: 48 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| BMS-986036 Dose Level 1 10 mg | Correlation | -0.202 r-correlation |
| BMS-986036 Dose Level 2 20 mg | Correlation | -0.047 r-correlation |
| BMS-986036 Dose Level 3 40 mg | Correlation | 0.248 r-correlation |
| Placebo | Correlation | -0.044 r-correlation |
Secondary
Correlation
Correlation of MBT changes to changes in Serum Pro-C3 results from Day 1 to Week 48
Time frame: 48 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| BMS-986036 Dose Level 1 10 mg | Correlation | -0.001 r-correlation |
| BMS-986036 Dose Level 2 20 mg | Correlation | 0.242 r-correlation |
| BMS-986036 Dose Level 3 40 mg | Correlation | -0.263 r-correlation |
| Placebo | Correlation | -0.072 r-correlation |
Secondary
Correlation
Correlation of MBT changes to changes in liver elastography by Fibroscan (in cohort 2 only) from Day 1 to Week 48
Time frame: 48 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| BMS-986036 Dose Level 1 10 mg | Correlation | 0.491 r-correlation |
| BMS-986036 Dose Level 2 20 mg | Correlation | -0.351 r-correlation |
| BMS-986036 Dose Level 3 40 mg | Correlation | -0.121 r-correlation |
| Placebo | Correlation | -0.43 r-correlation |
Secondary
Correlation
Correlation of MBT changes to changes in MELD (model for end-stage liver disease) scores (in cohort 2 only) from Day 1 to Week 48.The MELD score is generally calculated as: MELD = 3.78×ln\[serum bilirubin (mg/dL)\] + 11.2×ln\[INR\] + 9.57×ln\[serum creatinine (mg/dL)\] + 6.43. The higher the score, the more chances of mortality.
Time frame: 48 weeks
Population: The objective of this endpoint was to compare changes in MBT collected for all subjects versus changes in MELD, a clinically used parameter used to assess liver function in each arm, over the course of the participation time in this trial, The result value is N/A if there were no subjects that had a MELD value that changed over the course of the trial, rendering r-correlation evaluation of changes in MBT versus changes in MELD not applicable.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| BMS-986036 Dose Level 1 10 mg | Correlation | NA r-correlation |
| BMS-986036 Dose Level 2 20 mg | Correlation | NA r-correlation |
| BMS-986036 Dose Level 3 40 mg | Correlation | NA r-correlation |
| Placebo | Correlation | NA r-correlation |
Secondary
Correlation
Correlation of MBT changes to changes in CTP (Child-Turcotte-Pugh) score form Day 1 to Week 48. The CTP score is based on the sum of the ranges of the following parameters: total bilirubin (1-3), serum albumin (1-3), prothrombin time (1-3), ascites level (1-3) and hepatic encephalopathy grade (1-3). The higher the score, the more advanced is the liver disease
Time frame: 48 weeks
Population: The objective of this endpoint was to compare changes in MBT collected for all subjects versus changes in CTP, a clinically used parameter used to assess liver function, in each arm, over the course of the participation time in this trial, The result value is N/A if there were no subjects that had a CTP value that changed over the course of the trial, rendering r-correlation evaluation of changes in MBT versus changes in CTP not applicable.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| BMS-986036 Dose Level 1 10 mg | Correlation | NA r-correlation |
| BMS-986036 Dose Level 2 20 mg | Correlation | NA r-correlation |
| BMS-986036 Dose Level 3 40 mg | Correlation | NA r-correlation |
| Placebo | Correlation | NA r-correlation |
Secondary
Number of Subjects That Experience Deterioration Events
Binary diagnosis of subjects that experience deterioration event as determined by the MBT compared to the placebo treatment arm
Time frame: 48 weeks
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| BMS-986036 Dose Level 1 10 mg | Number of Subjects That Experience Deterioration Events | 0 Participants |
| BMS-986036 Dose Level 2 20 mg | Number of Subjects That Experience Deterioration Events | 0 Participants |
| BMS-986036 Dose Level 3 40 mg | Number of Subjects That Experience Deterioration Events | 0 Participants |
| Placebo | Number of Subjects That Experience Deterioration Events | 0 Participants |